HTFL vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HTFL exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position (Current Ratio 5.20) and impressive revenue growth of 40.5%, these are offset by deep negative profit margins (-66.35%) and a high Price/Sales multiple of 13.13. The combination of heavy insider selling ($62.54M) and consistent earnings misses suggests a significant disconnect between analyst optimism and internal sentiment.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HTFL vs MRK: Head-to-Head Comparison
This page compares Heartflow, Inc. (HTFL) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.